<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2122">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928758</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY911</org_study_id>
    <secondary_id>P50DA036107</secondary_id>
    <nct_id>NCT01928758</nct_id>
  </id_info>
  <brief_title>Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders</brief_title>
  <official_title>Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this project is to evaluate the effect of progressive nicotine reduction&#xD;
      in cigarettes on smoking behavior, toxin exposure and psychiatric symptoms in smokers with&#xD;
      comorbid mood and/or anxiety disorders.&#xD;
&#xD;
      Smokers with mood and/or anxiety disorder will smoke research cigarettes that will contain&#xD;
      either a) nicotine content similar to their preferred usual brand of cigarettes, or b)&#xD;
      nicotine content per cigarette that is progressively reduced from approximately 11.6 mg to&#xD;
      0.2 mg per cigarette over 18 weeks.&#xD;
&#xD;
      It is our hypothesis that nicotine intake will decline as a function of cigarette nicotine&#xD;
      content in the Reduced Nicotine Content group without significant increases in tobacco smoke&#xD;
      exposure, severity of nicotine withdrawal symptoms, mood and anxiety symptomatology or&#xD;
      protocol non-adherence over time in the Reduced Nicotine Content group as compared with the&#xD;
      control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall aim of this project is to evaluate the effect of progressive nicotine reduction&#xD;
      in cigarettes on smoking behavior, toxicant exposure and psychiatric symptoms in smokers with&#xD;
      comorbid mood and/or anxiety disorders.&#xD;
&#xD;
      To do so, we will randomly assign 200 adult smokers with a unipolar mood and/or anxiety&#xD;
      disorder within the past year to smoke research cigarettes that will contain either a) Usual&#xD;
      Nicotine Content (UNC): nicotine content similar to their preferred usual brand of&#xD;
      cigarettes, or b) Reduced Nicotine Content (RNC): nicotine content per cigarette is&#xD;
      progressively reduced from approximately 11.6 mg to 0.2 mg per cigarette over 18 weeks. All&#xD;
      subjects will participate in baseline periods prior to double-blind randomization to assess&#xD;
      normal smoking behavior and then to establish ability to tolerate research cigarettes prior&#xD;
      to randomization.&#xD;
&#xD;
      A total of 280 participants will be enrolled in the study at two sites with the aim of&#xD;
      randomizing 200 who complete the baseline phase. 100 participants will be enrolled in the&#xD;
      randomized phase at Penn State Hershey and 100 at the Massachusetts General Hospital site.&#xD;
      Participants will be started on the study protocol during Baseline I and Baseline II but will&#xD;
      be removed from the study if they are not able to comply with the protocol. We expect that&#xD;
      approximately 40 participants at each site drop out from the study prior to randomization&#xD;
      (due to inability to comply with study protocol).&#xD;
&#xD;
      It is our hypothesis that nicotine intake, as measured by plasma cotinine concentration, will&#xD;
      decline as a function of cigarette nicotine content in the RNC group. Further, it is our&#xD;
      hypothesis that by gradually reducing the nicotine content of the cigarettes in a step-wise&#xD;
      fashion, there will not be significant increases in biomarkers of tobacco smoke exposure,&#xD;
      severity of nicotine withdrawal symptoms, mood and anxiety symptomatology or protocol&#xD;
      non-adherence over time in the experimental group (RNC) as compared with the UNC control&#xD;
      group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">March 23, 2018</completion_date>
  <primary_completion_date type="Actual">January 11, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Cotinine Concentration</measure>
    <time_frame>Measured at the end of the last 3 weeks of randomization trial phase</time_frame>
    <description>Plasma cotinine is a measure of daily nicotine exposure. Samples were measured in ng/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptomatology</measure>
    <time_frame>Measured at the end of the last 3 weeks of randomization trial phase</time_frame>
    <description>A 16-item scale on depression symptoms. The scale range is 0-27 where 0 = Least Severe and 27 = Most Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Stress Scale</measure>
    <time_frame>Measured at the end of the last 3 weeks of randomization trial phase</time_frame>
    <description>10-item questionnaire measuring the degree to which life situations are appraised stressful. Scale range is 0-40. Higher scores indicate more stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Nicotine Withdrawal Scale</measure>
    <time_frame>Measured at the end of the last 3 weeks of randomization trial phase</time_frame>
    <description>This 8-item scale measures nicotine withdrawal symptoms and the scale range is from 0-32. Higher scores indicate higher severity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intention to Quit Smoking</measure>
    <time_frame>At end of 18-week randomized trial phase</time_frame>
    <description>Smokers assigned to the reduced nicotine content cigarette group may have lower perceived dependence and be more likely to report intention to quit smoking</description>
  </other_outcome>
  <other_outcome>
    <measure>Abstinence From Smoking</measure>
    <time_frame>Follow-up appointment 30 weeks after randomization (12 weeks after last visit of randomized trial phase).</time_frame>
    <description>Smokers assigned to reduced nicotine content cigarettes will be more likely to successfully abstain from smoking at the end of the trial, based on all randomized participants, defined as no cigarette use in past 7 days, verified by exhaled carbon monoxide &lt;10ppm.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>Reduced Nicotine Content Cigarettes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Nicotine Content Cigarettes</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Research cigarettes with a usual nicotine content (around 11.6mg per cigarette)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduced Nicotine Content Cigarettes</intervention_name>
    <description>Research cigarettes will have gradually reduced nicotine content</description>
    <arm_group_label>Reduced Nicotine Content Cigarettes</arm_group_label>
    <other_name>Nicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual Nicotine Content Cigarettes</intervention_name>
    <description>Usual Nicotine Content Cigarettes</description>
    <arm_group_label>Usual Nicotine Content Cigarettes</arm_group_label>
    <other_name>Nicotine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Smoke &gt;4 cigarettes/day for at least a year&#xD;
&#xD;
          -  No quit attempt in prior month&#xD;
&#xD;
          -  Not planning to quit smoking within next 6 months&#xD;
&#xD;
          -  Plan to live in local area for next 8 months&#xD;
&#xD;
          -  Meet diagnostic criteria for a current or lifetime Anxiety Disorder or Mood Disorder&#xD;
             as determined by the Mini-international Neuropsychiatric Interview&#xD;
&#xD;
          -  Read and write in English&#xD;
&#xD;
          -  Women not pregnant or nursing and taking steps to avoid pregnancy&#xD;
&#xD;
          -  Able to understand and consent to study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable or significant medical condition such as Chronic Obstructive Pulmonary&#xD;
             Disease or kidney failure&#xD;
&#xD;
          -  Use of non-cigarette nicotine delivery product in the past week or smoking cessation&#xD;
             medicine in prior month&#xD;
&#xD;
          -  Currently reducing or planning to reduce cigarette consumption in next month&#xD;
&#xD;
          -  Uncontrolled serious psychotic illness or substance abuse or inpatient treatment for&#xD;
             these in the past 6 months&#xD;
&#xD;
          -  Current suicide risk on clinical assessment&#xD;
&#xD;
          -  Aged &lt;18 or &gt;65&#xD;
&#xD;
          -  History of difficulty providing blood samples (fainting, poor venous access)&#xD;
&#xD;
          -  Unwilling to remain on one flavor of cigarette (regular or menthol) for the duration&#xD;
             of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan A Foulds, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Eden Evins, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Allen SI, Foulds J, Pachas GN, Veldheer S, Cather C, Azzouz N, Hrabovsky S, Hameed A, Yingst J, Hammett E, Modesto J, Krebs NM, Zhu J, Liao J, Muscat JE, Richie J, Evins AE. A two-site, two-arm, 34-week, double-blind, parallel-group, randomized controlled trial of reduced nicotine cigarettes in smokers with mood and/or anxiety disorders: trial design and protocol. BMC Public Health. 2017 Jan 19;17(1):100. doi: 10.1186/s12889-016-3946-4.</citation>
    <PMID>28103841</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>August 21, 2013</study_first_submitted>
  <study_first_submitted_qc>August 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2013</study_first_posted>
  <results_first_submitted>January 11, 2019</results_first_submitted>
  <results_first_submitted_qc>January 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2019</results_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Jonathan Foulds</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Nicotine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT01928758/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>27 participants attended Visit 1 and consented but did not meet final eligibility criteria. The remaining participants (n=218) began a baseline phase during which 30 participants were lost to follow up or withdrawn from the study before being randomized to the study intervention. 188 participants were randomized into an intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Reduced Nicotine Content Cigarettes</title>
          <description>The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks&#xD;
Reduced Nicotine Content Cigarettes: Research cigarettes will have gradually reduced nicotine content</description>
        </group>
        <group group_id="P2">
          <title>Usual Nicotine Content Cigarettes</title>
          <description>Research cigarettes with a nicotine content similar to participant's usual brand of cigarettes (around 11.6mg)&#xD;
Usual Nicotine Content Cigarettes: Usual Nicotine Content Cigarettes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline values for outcomes reflect levels after participants were on the usual nicotine content cigarettes for 2 weeks and before they received the intervention.</population>
      <group_list>
        <group group_id="B1">
          <title>Reduced Nicotine Content Cigarettes</title>
          <description>The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks&#xD;
Reduced Nicotine Content Cigarettes: Research cigarettes will have gradually reduced nicotine content</description>
        </group>
        <group group_id="B2">
          <title>Usual Nicotine Content Cigarettes</title>
          <description>Research cigarettes with a nicotine content similar to participant's usual brand of cigarettes (around 11.6mg)&#xD;
Usual Nicotine Content Cigarettes: Usual Nicotine Content Cigarettes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="94"/>
            <count group_id="B3" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.3" spread="11.7"/>
                    <measurement group_id="B2" value="43.1" spread="13.3"/>
                    <measurement group_id="B3" value="43.2" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian/white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American/black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Pacific Island</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaskan native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menthol smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quick Inventory of Depressive Symptomatology</title>
          <description>The 16-item scale uses a continuous score and the scale range is 0-27 where 0 = Least Severe and 27 = Most Severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="4.8"/>
                    <measurement group_id="B2" value="6.3" spread="4.3"/>
                    <measurement group_id="B3" value="5.9" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Perceived Stress Scale</title>
          <description>10-item version was used. Scale range is 0-40. Higher scores indicate more stress.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.0" spread="7.5"/>
                    <measurement group_id="B2" value="17.1" spread="8.2"/>
                    <measurement group_id="B3" value="16.5" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Overall Anxiety Severity and Impairment Scale</title>
          <description>The OASIS is a 5-item scale to measure overall anxiety severity and impairment. The range is 0-20 where higher scores indicate higher anxiety.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="4.1"/>
                    <measurement group_id="B2" value="5.7" spread="4.3"/>
                    <measurement group_id="B3" value="5.3" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Kessler-6 Scale</title>
          <description>The Kessler-6 Scale is a 6-item scale with a total possible score range from 0-24 used to define serious psychological distress. Higher scores indicate more distress.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="5.4"/>
                    <measurement group_id="B2" value="6.5" spread="5.1"/>
                    <measurement group_id="B3" value="6.1" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes per day</title>
          <units>cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.2" spread="10.7"/>
                    <measurement group_id="B2" value="21.6" spread="10.6"/>
                    <measurement group_id="B3" value="20.9" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Exhaled Carbon Monoxide</title>
          <units>parts per million</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.4" spread="17.7"/>
                    <measurement group_id="B2" value="29.1" spread="15.1"/>
                    <measurement group_id="B3" value="29.3" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma Cotinine</title>
          <description>Cotinine values below the assay Limit of Detection (LOD) are imputed using a common substitution formula (LOD/ square root of 2), which in the case of plasma cotinine equals 3 ng/mL.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="245.7" spread="137.2"/>
                    <measurement group_id="B2" value="255.9" spread="145.5"/>
                    <measurement group_id="B3" value="250.9" spread="141.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Minnesota Nicotine Withdrawal Scale</title>
          <description>The scale range is from 0-32 and includes 8 items. The scale is used to measure signs of nicotine withdrawal where higher scores indicate higher severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.9" spread="7.3"/>
                    <measurement group_id="B2" value="10.5" spread="6.3"/>
                    <measurement group_id="B3" value="10.2" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Cotinine Concentration</title>
        <description>Plasma cotinine is a measure of daily nicotine exposure. Samples were measured in ng/mL.</description>
        <time_frame>Measured at the end of the last 3 weeks of randomization trial phase</time_frame>
        <population>Randomized trial phase completers with non-missing values for the outcome at both time points being used in the regression (complete case analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Nicotine Content Cigarettes</title>
            <description>The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks&#xD;
Reduced Nicotine Content Cigarettes: Research cigarettes will have gradually reduced nicotine content</description>
          </group>
          <group group_id="O2">
            <title>Usual Nicotine Content Cigarettes</title>
            <description>Research cigarettes with a nicotine content similar to participant's usual brand of cigarettes (around 11.6mg)&#xD;
Usual Nicotine Content Cigarettes: Usual Nicotine Content Cigarettes</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cotinine Concentration</title>
          <description>Plasma cotinine is a measure of daily nicotine exposure. Samples were measured in ng/mL.</description>
          <population>Randomized trial phase completers with non-missing values for the outcome at both time points being used in the regression (complete case analysis).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" spread="154.3"/>
                    <measurement group_id="O2" value="259.0" spread="151.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Complete case analysis</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Model was adjusted for baseline cotinine after smoking usual nicotine content cigarettes for 2-weeks.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-175.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-218.3</ci_lower_limit>
            <ci_upper_limit>-133.1</ci_upper_limit>
            <estimate_desc>The direction of comparison is reduced nicotine content vs. usual nicotine content cigarette treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quick Inventory of Depressive Symptomatology</title>
        <description>A 16-item scale on depression symptoms. The scale range is 0-27 where 0 = Least Severe and 27 = Most Severe.</description>
        <time_frame>Measured at the end of the last 3 weeks of randomization trial phase</time_frame>
        <population>Randomized trial phase completers with non-missing values for the outcome at both time points being used in the regression (complete case analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Nicotine Content Cigarettes</title>
            <description>The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks&#xD;
Reduced Nicotine Content Cigarettes: Research cigarettes will have gradually reduced nicotine content</description>
          </group>
          <group group_id="O2">
            <title>Usual Nicotine Content Cigarettes</title>
            <description>Research cigarettes with a nicotine content similar to participant's usual brand of cigarettes (around 11.6mg)&#xD;
Usual Nicotine Content Cigarettes: Usual Nicotine Content Cigarettes</description>
          </group>
        </group_list>
        <measure>
          <title>Quick Inventory of Depressive Symptomatology</title>
          <description>A 16-item scale on depression symptoms. The scale range is 0-27 where 0 = Least Severe and 27 = Most Severe.</description>
          <population>Randomized trial phase completers with non-missing values for the outcome at both time points being used in the regression (complete case analysis).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="4.3"/>
                    <measurement group_id="O2" value="5.3" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <p_value_desc>Complete case analysis</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Model was adjusted for baseline score after smoking usual nicotine content cigarettes for 2 weeks</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
            <estimate_desc>The direction of comparison is reduced nicotine content vs. usual nicotine content cigarette treatment group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceived Stress Scale</title>
        <description>10-item questionnaire measuring the degree to which life situations are appraised stressful. Scale range is 0-40. Higher scores indicate more stress.</description>
        <time_frame>Measured at the end of the last 3 weeks of randomization trial phase</time_frame>
        <population>Randomized trial phase completers with non-missing values for the outcome at both time points being used in the regression (complete case analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Nicotine Content Cigarettes</title>
            <description>The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks&#xD;
Reduced Nicotine Content Cigarettes: Research cigarettes will have gradually reduced nicotine content</description>
          </group>
          <group group_id="O2">
            <title>Usual Nicotine Content Cigarettes</title>
            <description>Research cigarettes with a nicotine content similar to participant's usual brand of cigarettes (around 11.6mg)&#xD;
Usual Nicotine Content Cigarettes: Usual Nicotine Content Cigarettes</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived Stress Scale</title>
          <description>10-item questionnaire measuring the degree to which life situations are appraised stressful. Scale range is 0-40. Higher scores indicate more stress.</description>
          <population>Randomized trial phase completers with non-missing values for the outcome at both time points being used in the regression (complete case analysis).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="7.6"/>
                    <measurement group_id="O2" value="15.1" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <p_value_desc>Complete case analysis</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Model was adjusted for baseline score after smoking usual nicotine content cigarettes for 2 weeks</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.40</ci_lower_limit>
            <ci_upper_limit>2.16</ci_upper_limit>
            <estimate_desc>The direction of comparison is reduced nicotine content vs. usual nicotine content cigarette treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minnesota Nicotine Withdrawal Scale</title>
        <description>This 8-item scale measures nicotine withdrawal symptoms and the scale range is from 0-32. Higher scores indicate higher severity.</description>
        <time_frame>Measured at the end of the last 3 weeks of randomization trial phase</time_frame>
        <population>Randomized trial phase completers with non-missing values for the outcome at both time points being used in the regression (complete case analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Nicotine Content Cigarettes</title>
            <description>The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks&#xD;
Reduced Nicotine Content Cigarettes: Research cigarettes will have gradually reduced nicotine content</description>
          </group>
          <group group_id="O2">
            <title>Usual Nicotine Content Cigarettes</title>
            <description>Research cigarettes with a nicotine content similar to participant's usual brand of cigarettes (around 11.6mg)&#xD;
Usual Nicotine Content Cigarettes: Usual Nicotine Content Cigarettes</description>
          </group>
        </group_list>
        <measure>
          <title>Minnesota Nicotine Withdrawal Scale</title>
          <description>This 8-item scale measures nicotine withdrawal symptoms and the scale range is from 0-32. Higher scores indicate higher severity.</description>
          <population>Randomized trial phase completers with non-missing values for the outcome at both time points being used in the regression (complete case analysis).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="6.8"/>
                    <measurement group_id="O2" value="9.0" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <p_value_desc>Complete case analysis</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Model was adjusted for baseline score after smoking usual nicotine content cigarettes for 2 weeks</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.68</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>The direction of comparison is reduced nicotine content vs. usual nicotine content cigarette treatment group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Intention to Quit Smoking</title>
        <description>Smokers assigned to the reduced nicotine content cigarette group may have lower perceived dependence and be more likely to report intention to quit smoking</description>
        <time_frame>At end of 18-week randomized trial phase</time_frame>
        <population>Participants who attended the visit at the end of the 18-week randomized trial phase</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Nicotine Content Cigarettes</title>
            <description>The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks&#xD;
Reduced Nicotine Content Cigarettes: Research cigarettes will have gradually reduced nicotine content</description>
          </group>
          <group group_id="O2">
            <title>Usual Nicotine Content Cigarettes</title>
            <description>Research cigarettes with a usual nicotine content (around 11.6mg per cigarette)&#xD;
Usual Nicotine Content Cigarettes: Usual Nicotine Content Cigarettes</description>
          </group>
        </group_list>
        <measure>
          <title>Intention to Quit Smoking</title>
          <description>Smokers assigned to the reduced nicotine content cigarette group may have lower perceived dependence and be more likely to report intention to quit smoking</description>
          <population>Participants who attended the visit at the end of the 18-week randomized trial phase</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Abstinence From Smoking</title>
        <description>Smokers assigned to reduced nicotine content cigarettes will be more likely to successfully abstain from smoking at the end of the trial, based on all randomized participants, defined as no cigarette use in past 7 days, verified by exhaled carbon monoxide &lt;10ppm.</description>
        <time_frame>Follow-up appointment 30 weeks after randomization (12 weeks after last visit of randomized trial phase).</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Nicotine Content Cigarettes</title>
            <description>The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks&#xD;
Reduced Nicotine Content Cigarettes: Research cigarettes will have gradually reduced nicotine content</description>
          </group>
          <group group_id="O2">
            <title>Usual Nicotine Content Cigarettes</title>
            <description>Research cigarettes with a nicotine content similar to participant's usual brand of cigarettes (around 11.6mg)&#xD;
Usual Nicotine Content Cigarettes: Usual Nicotine Content Cigarettes</description>
          </group>
        </group_list>
        <measure>
          <title>Abstinence From Smoking</title>
          <description>Smokers assigned to reduced nicotine content cigarettes will be more likely to successfully abstain from smoking at the end of the trial, based on all randomized participants, defined as no cigarette use in past 7 days, verified by exhaled carbon monoxide &lt;10ppm.</description>
          <population>All randomized participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All randomized participants throughout the entire 33 weeks of the trial.</time_frame>
      <desc>Adverse events (AEs) were systematically collected at each study visit by asking participants about any changes in their physical or mental health or if they needed to seek immediate medical care at an emergency room or hospital.</desc>
      <group_list>
        <group group_id="E1">
          <title>Reduced Nicotine Content Cigarettes</title>
          <description>The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 8.6, 4.0, 1.8, 0.9 and 0.3 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks&#xD;
Reduced Nicotine Content Cigarettes: Research cigarettes will have gradually reduced nicotine content</description>
        </group>
        <group group_id="E2">
          <title>Usual Nicotine Content Cigarettes</title>
          <description>Research cigarettes with a nicotine content similar to participant's usual brand of cigarettes (around 11.6mg)&#xD;
Usual Nicotine Content Cigarettes: Usual Nicotine Content Cigarettes</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other</sub_title>
                <description>Blocked artery</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Endocarditis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other</sub_title>
                <description>Lung and leg infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other</sub_title>
                <description>Accidental drug overdose</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other</sub_title>
                <description>Rhabdomyolysis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders - Other</sub_title>
                <description>Drug relapse</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other</sub_title>
                <description>Dog bite requiring surgery</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="94"/>
                <counts group_id="E2" events="30" subjects_affected="24" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="94"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="39" subjects_affected="30" subjects_at_risk="94"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="94"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample size was not reached due to a shortage of study cigarette inventory.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jonathan Foulds</name_or_title>
      <organization>Penn State College of Medicine</organization>
      <phone>717-531-3504</phone>
      <email>jfoulds@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

